Skip to main content
Clinical Trials/CTIS2024-513576-18-00
CTIS2024-513576-18-00
Active, not recruiting
Phase 1

Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01 - RC31/17-0213

Centre Hospitalier Universitaire De Toulouse0 sites310 target enrollmentApril 26, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cervical Cancer
Sponsor
Centre Hospitalier Universitaire De Toulouse
Enrollment
310
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 26, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patient with cervical cancer WITH para\-aortic lymph node involvement determined by either a positive 18F\-FDG PET\-CT (visual interpretation of metabolic activity of para\-aortic lymph node, greater than the background noise), or by histological examination of para\-aortic lymph nodes if negative 18F\-FDG PET\-CT, Signed written informed consent, Affiliated to a social security insurance or equivalent, Age \=18 years, ECOG performance status of 0 to 2, FIGO stage IIIC2 or IVA WITH para\-aortic lymph node involvement at the time of diagnosis, Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma, Normal renal function (creatinine clearance \=60 mL/min), Normal liver function (total bilirubin \<1\.5 times the upper limit of normal (ULN) and AST \<3 ULN), Normal haematological assessment (platelets \>100×109/L and neutrophils \>1\.5×109/L), Women of childbearing potential and not postmenopausal must have a negative blood serum or urine pregnancy test before starting the study treatment

Exclusion Criteria

  • Patients who have received prior chemotherapy or radiotherapy for their cervical cancer, Pregnant or breastfeeding women, History of invasive cancer (in the last five years) other than non\-melanoma skin cancer, Acute, uncontrolled cardiovascular disease, Peripheral neuropathy of CTCAE grade 3\-4, Known hypersensitivity to Paclitaxel, Cisplatin or other platinum\-containing compounds, Patients under legal protection

Outcomes

Primary Outcomes

Not specified

Similar Trials